NRx Pharmaceuticals (NRXP) 10-Q14 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2024	Nov. 14, 2024
Document Information [Line Items]
Entity Central Index Key	0001719406
Entity Registrant Name	NRX Pharmaceuticals, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-38302
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2844431
Entity Address, Address Line One	1201 Orange Street, Suite 600
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19801
City Area Code	484
Local Phone Number	254-6134
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,094,094
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	NRXPW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	NRXP
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 1,646	$ 4,595
Prepaid expense and other current assets	2,460	2,289
Total current assets	4,106	6,884
Other assets	356	431
Total assets	4,462	7,315
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	4,866	4,632
Accrued and other current liabilities	9,444	4,714
Accrued clinical site costs	403	524
Convertible note payable and accrued interest, current	3,050	9,161
Insurance loan payable	634	0
Warrant liabilities	1,902	17
Total current liabilities	20,299	19,048
Convertible note payable and accrued interest, long term	2,985	0
Total liabilities	23,284	19,048
Commitments and Contingencies (Note 8)
Common stock, $0.001 par value, 500,000,000 shares authorized; 11,373,246 and 8,391,940 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	11	8
Additional paid-in capital	250,362	241,406
Accumulated other comprehensive loss	0	(3)
Accumulated deficit	(269,195)	(253,147)
Total stockholders’ deficit	(18,822)	(11,733)
Total liabilities and stockholders' deficit	4,462	7,315
Nondesignated Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 50,000,000 shares authorized.	0	0
Series A Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value, 50,000,000 shares authorized.	$ 0	$ 3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, authorized (in shares)	50,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	11,373,246	8,391,940
Common stock, outstanding (in shares)	11,373,246	8,391,940
Nondesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	50,000,000	50,000,000
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	12,000,000	12,000,000
Preferred stock, issued (in shares)	0	3,000,000
Preferred stock, outstanding (in shares)	0	3,000,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expense:
Research and development	$ 611	$ 3,314	$ 5,163	$ 10,837
General and administrative	2,411	2,494	10,907	12,344
Settlement expense	0	0	0	250
Total operating expenses	3,022	5,808	16,070	23,431
Loss from operations	(3,022)	(5,808)	(16,070)	(23,431)
Other (income) expense:
Interest income	(6)	(119)	(40)	(420)
Interest expense	0	40	230	40
Convertible note default penalty	0	0	849	0
Change in fair value of convertible notes payable	(1,355)	359	(1,014)	2,794
Change in fair value of warrant liabilities	(165)	(26)	(174)	(27)
Loss on convertible note redemptions	127	0	127	0
Total other (income) expense	(1,399)	254	(22)	2,387
Net loss	(1,623)	(6,062)	(16,048)	(25,818)
Comprehensive loss:
Change in fair value of convertible note attributed to credit risk	3	0	3	22
Other comprehensive loss	3	0	3	22
Comprehensive loss	$ (1,626)	$ (6,062)	$ (16,051)	$ (25,840)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.15)	$ (0.74)	$ (1.59)	$ (3.48)
Weighted average common shares outstanding:
Basic and diluted (in shares)	10,973,697	8,194,696	10,108,859	7,411,418

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock and Warrant Issuance [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock and Warrant Issuance [Member] Preferred Stock [Member]	Common Stock and Warrant Issuance [Member] Common Stock [Member]	Common Stock and Warrant Issuance [Member] Additional Paid-in Capital [Member]	Common Stock and Warrant Issuance [Member] Retained Earnings [Member]	Common Stock and Warrant Issuance [Member] AOCI Attributable to Parent [Member]	Common Stock and Warrant Issuance [Member]	ATM Offering [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	ATM Offering [Member] Preferred Stock [Member]	ATM Offering [Member] Common Stock [Member]	ATM Offering [Member] Additional Paid-in Capital [Member]	ATM Offering [Member] Retained Earnings [Member]	ATM Offering [Member] AOCI Attributable to Parent [Member]	ATM Offering [Member]	Private Placement [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member]	Share Subscription Facility Agreement - GEM [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Share Subscription Facility Agreement - GEM [Member] Preferred Stock [Member]	Share Subscription Facility Agreement - GEM [Member] Common Stock [Member]	Share Subscription Facility Agreement - GEM [Member] Additional Paid-in Capital [Member]	Share Subscription Facility Agreement - GEM [Member] Retained Earnings [Member]	Share Subscription Facility Agreement - GEM [Member] AOCI Attributable to Parent [Member]	Share Subscription Facility Agreement - GEM [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2022																													0	0	6,644,299
Balance at Dec. 31, 2022																													$ 0	$ 0	$ 7	$ 230,399	$ (222,997)	$ 0	$ 7,409
Stock-based compensation																													0	0	0	695	0	0	695
Stock issuances, net (in shares)	0	0	386,667
Stock issuances, net	$ 0	$ 0	$ 0	$ 2,545	$ 0	$ 0	$ 2,545
Net loss																													$ 0	$ 0	$ 0	0	(11,039)	0	(11,039)
Balance (in shares) at Mar. 31, 2023																													0	0	7,030,966
Change in fair value of convertible note attributed to credit risk																													$ 0	$ 0	$ 0	0	0	106	106
Balance at Mar. 31, 2023																													$ 0	$ 0	$ 7	233,639	(234,036)	106	(284)
Balance (in shares) at Dec. 31, 2022																													0	0	6,644,299
Balance at Dec. 31, 2022																													$ 0	$ 0	$ 7	230,399	(222,997)	0	7,409
Net loss																																			(25,818)
Balance (in shares) at Sep. 30, 2023																													3,000,000,000	0	8,391,956,000
Change in fair value of convertible note attributed to credit risk																																			(22)
Balance at Sep. 30, 2023																													$ 3	$ 0	$ 8	242,609	(248,815)	(22)	(6,217)
Balance (in shares) at Mar. 31, 2023																													0	0	7,030,966
Balance at Mar. 31, 2023																													$ 0	$ 0	$ 7	233,639	(234,036)	106	(284)
Stock-based compensation																													$ 0	$ 0	$ 0	544	0	0	544
Stock issuances, net (in shares)	0	0	967,000
Stock issuances, net	$ 0	$ 0	$ 1	5,576	0	0	5,577
Shares issued as repayment of principal and interest for convertible note (in shares)																													0	0	40,867
Shares issued as repayment of principal and interest for convertible note																													$ 0	$ 0	$ 0	200	0	0	200
Net loss																													$ 0	$ 0	$ 0	0	(8,717)	0	(8,717)
Balance (in shares) at Jun. 30, 2023																													0	0	8,038,833
Change in fair value of convertible note attributed to credit risk																													$ 0	$ 0	$ 0	0	0	(128)	(128)
Balance at Jun. 30, 2023																													0	0	8	239,959	(242,753)	(22)	(2,808)
Stock-based compensation																													0	0	0	351	0	0	351
Conversion of Series A preferred stock into common stock																													$ 0	$ 0	$ 0	782	0	0	782
Stock issuances, net (in shares)																						0	0	67,568
Stock issuances, net																						$ 0	$ 0	$ 0	$ 250	$ 0	$ 0	$ 250
Shares issued as repayment of principal and interest for convertible note (in shares)																													0	0	285,555
Net loss																													$ 0	$ 0	$ 0	0	(6,062)	0	(6,062)
Balance (in shares) at Sep. 30, 2023																													3,000,000,000	0	8,391,956,000
Change in fair value of convertible note attributed to credit risk																																			0
Preferred stock and warrants issued, net of issuance costs $27 (in shares)																													3,000,000	0	0
Preferred stock and warrants issued, net of issuance costs $27																													$ 3	$ 0	$ 0	1,168	0	0	1,171
Adjustment for deferred offering cost settlement																													0	0	0	99	0	0	99
Balance at Sep. 30, 2023																													$ 3	$ 0	$ 8	242,609	(248,815)	(22)	(6,217)
Balance (in shares) at Dec. 31, 2023																													3,000,000	0	8,391,940
Balance at Dec. 31, 2023																													$ 3	$ 0	$ 8	241,406	(253,147)	(3)	(11,733)
Stock-based compensation																													$ 0	$ 0	$ 0	242	0	0	242
Conversion of Series A preferred stock into common stock (in shares)																														0	300,000
Conversion of Series A preferred stock into common stock																														$ 0	$ 0	3	0	0	0
Conversion of Series A preferred stock into common stock (in shares)																													(3,000,000)
Conversion of Series A preferred stock into common stock																													$ (3)
Stock issuances, net (in shares)	0	0	575,000					0	0	34,584					0	0	270,000
Stock issuances, net	$ 0	$ 0	$ 1	1,343	0		1,344	$ 0	$ 0	$ 0	$ 179	$ 0	$ 0	$ 179	$ 0	$ 0	$ 0	$ 1,027	$ 0	$ 0	$ 1,027
Warrants issued pursuant to the Alvogen Agreement amendment (see Note 6)																													$ 0	$ 0	$ 0	0	0	0	0
Vesting of restricted stock awards (in shares)																													0	0	57,500
Vesting of restricted stock awards																													$ 0	$ 0	$ 0	0	0	0	0
Shares issued as repayment of principal and interest for convertible note (in shares)																													0	0	143,648
Shares issued as repayment of principal and interest for convertible note																													$ 0	$ 0	$ 1	399	0	0	400
Net loss																													$ 0	$ 0	$ 0	0	(6,528)	0	(6,528)
Balance (in shares) at Mar. 31, 2024																													0	0	9,772,672
Balance at Mar. 31, 2024																													$ 0	$ 0	$ 10	244,599	(259,675)	(3)	(15,069)
Balance (in shares) at Dec. 31, 2023																													3,000,000	0	8,391,940
Balance at Dec. 31, 2023																													$ 3	$ 0	$ 8	241,406	(253,147)	(3)	$ (11,733)
Stock issuances, net (in shares)																																			1,700,000
Net loss																																			$ (16,048)
Balance (in shares) at Sep. 30, 2024																													0	0	11,373,246
Change in fair value of convertible note attributed to credit risk																																			(3)
Balance at Sep. 30, 2024																													$ 0	$ 0	$ 11	250,362	(269,195)	0	(18,822)
Balance (in shares) at Mar. 31, 2024																													0	0	9,772,672
Balance at Mar. 31, 2024																													$ 0	$ 0	$ 10	244,599	(259,675)	(3)	(15,069)
Stock-based compensation																													0	0	0	97	0	0	97
Stock issuances, net (in shares)	0	0	698,050					0	0	247,868
Stock issuances, net	$ 0	$ 0	$ 1	$ 1,913	$ 0	$ 0	$ 1,914	$ 0	$ 0	$ 0	1,228	0	0	1,228
Net loss																													$ 0	$ 0	$ 0	0	(7,897)	0	(7,897)
Issuance of shares related to reverse stock split (in shares)																													0	0	73,040
Contract cost related to Alvogen termination (see Note 6)																													$ 0	$ 0	$ 0	1,336	0	0	1,336
Balance (in shares) at Jun. 30, 2024																													0	0	10,791,630
Balance at Jun. 30, 2024																													$ 0	$ 0	$ 11	249,173	(267,572)	(3)	(18,391)
Stock-based compensation																													$ 0	$ 0	$ 0	104	0	0	104
Stock issuances, net (in shares)								0	0	103,063
Stock issuances, net								$ 0	$ 0	$ 0	$ 219	$ 0	$ 0	$ 219
Shares issued as repayment of principal and interest for convertible note (in shares)																													0	0	458,553
Shares issued as repayment of principal and interest for convertible note																													$ 0	$ 0	$ 0	829	0	0	829
Net loss																													$ 0	$ 0	$ 0	0	(1,623)	0	(1,623)
Balance (in shares) at Sep. 30, 2024																													0	0	11,373,246
Common stock issued in exchange for services (in shares)																													0	0	20,000
Common stock issued in exchange for services																													$ 0	$ 0	$ 0	37	0	0	37
Reclassification of AOCI upon settlement of Streeterville Note																													0	0	0	0	0	3	3
Change in fair value of convertible note attributed to credit risk																																			(3)
Balance at Sep. 30, 2024																													$ 0	$ 0	$ 11	$ 250,362	$ (269,195)	$ 0	$ (18,822)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Common Stock and Warrant Issuance [Member]
Offering costs		$ 494	$ 481		$ 2,168	$ 351
ATM Offering [Member]
Offering costs	$ 31	$ 118	$ 48
Issuance costs				$ 27

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,048)	$ (25,818)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	4	4
Stock-based compensation	443	1,590
Common stock issued in exchange for services	37	0
Change in fair value of warrant liabilities	(174)	(27)
Change in fair value of convertible promissory notes	(1,011)	2,794
Loss on convertible note redemptions	127	0
Expense for debt issuance costs due to fair value election on Anson Notes	521	0
Warrant issuance costs related to Alvogen termination	1,336	0
Convertible note default penalty	849	0
Non-cash settlement expense	0	250
Changes in operating assets and liabilities:
Prepaid expense and other assets	(100)	1,554
Accounts payable	4,949	1,654
Insurance loan payable	634	0
Accrued expense and other liabilities	(106)	(466)
Net cash used in operating activities	(8,539)	(18,465)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment	0	(4)
Net cash used in investing activities	0	(4)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of convertible note	(4,800)	(2,288)
Repayment of insurance note	0	(474)
Expense for debt issuance costs due to fair value election on Anson Notes	(521)	0
Proceeds from issuance of insurance loan	0	786
Proceeds from Anson convertible note, net	2,941	0
Proceeds from liability classified warrants	2,059	0
Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs	0	1,171
Proceeds from issuance of common stock and warrants, net of issuance costs	4,884	0
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs	1,027	8,122
Net cash provided by financing activities	5,590	7,317
Net decrease in cash and cash equivalents	(2,949)	(11,152)
Cash and cash equivalents at beginning of period	4,595	20,054
Cash and cash equivalents at end of period	1,646	8,902
Supplemental disclosure of cash flow information:
Cash paid for interest	374	646
Cash paid for taxes	0	0
Non-cash investing and financing activities:
Issuance of common stock warrants as offering costs	188	75
Issuance of common stock for settlement of accrued liability	0	250
Conversion of Series A Preferred Stock to Common stock [Member]
Non-cash investing and financing activities:
Conversion of Series A preferred stock into common stock	3	0
Conversion of Principal and Interest Into Common Stock [Member]
Non-cash investing and financing activities:
Issuance of common stock as principal and interest repayment for convertible notes	$ 1,102	$ 982

Note 1 - Organization

Note 1 - Organization	9 Months Ended
Note 1 - Organization	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Business NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“ NRX Company NeuroRx HOPE Company we us our PTSD NMDA R&D two FDA PDUFA June 2025: 101, 100, February 2024, August 2024 7 Operations The Company’s drug development activities have expanded from its original focus on development of NRX- 101, 101 100/HTX 100

Note 2 - Going Concern

Note 2 - Going Concern	9 Months Ended
Note 2 - Going Concern	Sep. 30, 2024
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. Since inception, the Company has experienced net losses and negative cash flows from operations each fiscal year and has a working capital deficit at September 30, 2024 2024. 2025, first may not As of September 30, 2024 August 12, 2024, August 12, 2024 ( Purchase Agreement Investors Anson Notes 50% VWAP Anson Warrants first First Closing August 14, 2024 ( First Closing Date second Second Closing October 10, 2024 ( Second Closing Date The Company has secured operating capital that it anticipates as sufficient to fund its drug development operations through year end and to finance submission of FDA New Drug Applications for NRX- 100 101. may 2024 2025 may twelve not The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
Note 3 - Summary of Significant Accounting Policies	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. On April 1, 2024, Reverse Stock Split Common Stock 1 10 9. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP FASB ASC SEC not not may Use of Estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the fair value of the convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not may Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not third Fair Value of Financial Instruments FASB ASC Topic 820, Fair Value Measurements ASC 820 The accounting guidance classifies fair value measurements in one three Level 1: Level 2: 1 Level 3: no 11 Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not may, September 30, 2024 not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three may Revenue Recognition The Company accounts for revenue under FASB ASC Topic 606, Revenue for Contract with Customers ASC 606 not may may The Company enters into contractual arrangements that may 606, may The License Agreement (the “ License Agreement Alvogen 6 606. 606, 606, five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations within the contract; and v. recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five At contract inception, once the contract is determined to be within the scope of ASC 606, may not The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may not The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. The Company’s revenue arrangements may Milestone Payments first not Royalties Research Services 6 Research and Development Costs Research and development expense consists primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received. Non-cancellable Contracts The Company may may Convertible Notes Payable and Fair Value Election As permitted under FASB ASC Topic 825, ASC 825 The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg’s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At September 30, 2024, Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the condensed consolidated statements of operations and comprehensive loss based upon the underlying individual’s role at the Company. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ASC 480 815, Derivatives and Hedging ASC 815 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may Preferred Stock In accordance with ASC 480, not 815 40, Derivatives and Hedging Contracts in an Entity s Own Equity not not 815. Income Taxes Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ASC 740 not not 740. not not Loss Per Share The Company applies the two two no two not Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss. The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive. Nine months ended September 30, 2024 2023 Stock options 131,833 254,885 Restricted stock awards 33,333 66,667 Common stock warrants 5,327,636 3,302,159 Anson Note 3,236,280 — Convertible preferred stock — 300,000 Recent Accounting Pronouncements Not In November 2023, No. 2023‑07, 280 Improvements to Reportable Segment Disclosures (ASU 2023 07 2023 07 2023 07 December 15, 2023, December 15, 2024. In December 2023, 2023 09 740 mprovements to Income Tax Disclosures (ASU 2023 09 2023 09 2023 09 December 15, 2024.

Note 4 - Prepaid Expense and Ot

Note 4 - Prepaid Expense and Other Current Assets	9 Months Ended
Note 4 - Prepaid Expense and Other Current Assets	Sep. 30, 2024
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	4. Prepaid Expense and Other Current Assets Prepaid expense and other current assets consisted of the following at the dates indicated (in thousands): September 30, 2024 December 31, 2023 (Unaudited) Prepaid expense and other current assets: Prepaid insurance $ 1,185 $ 1,078 Prepaid clinical development costs 848 871 Other prepaid expense 421 334 Other current receivables 6 6 Total prepaid expense and other current assets $ 2,460 $ 2,289

Note 5 - Accrued and Other Curr

Note 5 - Accrued and Other Current Liabilities	9 Months Ended
Note 5 - Accrued and Other Current Liabilities	Sep. 30, 2024
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	5. Accrued and other current liabilities consisted of the following at the dates indicated (in thousands): September 30, 2024 December 31, 2023 (Unaudited) Accrued and other current liabilities: Refund liability (see Note 6) $ 4,715 $ — Professional services 3,573 2,686 Employee costs 324 835 Accrued research and development expense 592 1,112 Other accrued expense 240 81 Total accrued and other current liabilities $ 9,444 $ 4,714

Note 6 - Alvogen Licensing Agre

Note 6 - Alvogen Licensing Agreement	9 Months Ended
Note 6 - Alvogen Licensing Agreement	Sep. 30, 2024
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	6. In June 2023, 101, first 2b/3 First Milestone Payment February 2024, September 30, 2024 three 9 second first 2 first not September 3, 2024, not not Termination Under the License Agreement, as amended, Alvogen was granted early termination rights. On June 21, 2024, not September 30, 2024. Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination. As of September 30, 2024, September 30, 2024, 5 not June 2024

Note 7 - Debt

Note 7 - Debt	9 Months Ended
Note 7 - Debt	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Streeterville Convertible Note On November 4, 2022, Streeterville Note Streeterville The initial terms of the Streeterville Note included the following provisions, certain of which were subsequently modified, as described below. The Company had the option to prepay the Streeterville Note during the term by paying an amount equal to 110% of the principal, interest, and fees owed as of the prepayment date. The noteholder had the right to redeem up to $1.0 million of the outstanding balance of the Streeterville Note per month starting six Maximum Monthly Redemption Amount Redemption Premium Redemption Conversion Price two ten May 1, 2023, fifty 50% ten 10 thirty 30% ten 10 The Streeterville Note contained certain Trigger Events (as defined in the Streeterville Note) that generally, if uncured within five Event of Default Due to these embedded features within the Streeterville Note, the Company elected to account for the Streeterville Note at fair value at inception. Subsequent changes in fair value were recorded as a component of other income (loss) in the consolidated statements of operations. Convertible Note Amendments On March 30, 2023, First Amendment On July 7, 2023, #2 Second Amendment July 10, 2023, July 10, 2023. July 31, 2023, December 31, 2023, not July 31, 2023 December 31, 2023. On February 9, 2024, #3 Third Amendment February 12, 2024, February 12, 2024. February 29, 2024, July 31, 2024, first three not After April 30, 2024, July 31, 2024, July 31, 2024, July 31, 2024, August 31, 2024. not three September 30, 2024, During the Minimum Payment Period (defined in the Streeterville Note, as amended), the Company was permitted to pay the Redemption Amounts in the form of shares of Common Stock of the Company (the “ Redemption Conversion Shares Both the Second Amendment and the Third Amendment (considered cumulatively with the Second Amendment) were deemed to be debt modifications and did not 470, Debt not not Convertible Note Fair Value Measurements The Company estimated the fair value of the Streeterville Note using a Monte Carlo simulation model, which used as inputs the fair value of its Common Stock and estimated for the equity volatility and volume volatility of its Common Stock, the time to expiration of the Streeterville Note, the risk-free interest rate for a period that approximated the time to expiration, and probability of default. Therefore, the Company estimated its expected future volatility based on the actual volatility of its Common Stock and historical volatility of its Common Stock utilizing a lookback period consistent with the time to expiration. The time to expiration was based on the contractual maturity date, giving consideration to the mandatory and potential accelerated redemptions beginning six The discount to the principal amount was included in the carrying value of the Streeterville Note. During 2022, three nine September 30, 2024, three nine September 30, 2023, During the three nine September 30, 2024 three nine September 30, 2023, As of September 30, 2024 December 31, 2023 11 Alleged Default On April 24, 2024, Notice Spin-Off April 8, 2024, April 3, 2024 Streeterville also filed a complaint (the “ Complaint no On July 29, 2024, Streeterville Settlement On August 12, 2024, November 4, 2022 ( November 4, 2022, 60 second August 15, 2024. October 2024 ( 14 The Company evaluated the terms of the Settlement Amendment in accordance with ASC 470 50, Debt Modifications and Extinguishments not Topic 470,  Debt not not Anson Convertible Promissory Notes On August 12, 2024, In connection with the above offering, the Company engaged EF Hutton LLC as placement agent (the “Placement Agent”), Pursuant to the terms of the engagement with the Placement Agent, the Company will pay a cash fee of 7% of the gross proceeds the Company receives in the offering at closing.  2024 On August 14, 2024, first November 14, 2025 ( 9 On August 14, 2024, The First Tranche Notes are convertible at the option of the holder at any time after issuance into Common Stock, at a per share conversion price equal to the lower of (a) $2.4168, (the “Fixed Conversion Price”) or (b) a price equal to 92% of the lowest VWAP during the seven The terms of the First Tranche Notes do not 4.99% 9.99% 61 If the Company issues or grants options for Common Stock at a price lower than the current Conversion Price, the Conversion Price will be adjusted to match this lower price, (the “Base Conversion Price”). The Company must notify Anson of any such issuance, and Anson is entitled to convert shares based on the new Base Conversion Price. If the Company offers purchase rights to holders of Common Stock, Anson will be entitled to acquire those rights as if they had fully converted the Note, subject to the Beneficial Ownership Limitation. If exercising these rights would exceed the Beneficial Ownership Limitation, the rights will be held in abeyance until they can be exercised without exceeding the limit. The First Tranche Notes contain mandatory redemption features, whereby if at any time the First Tranche Notes are outstanding, the Company will be required to: (A) use up to 30% 1.05 not not 180 The First Tranche Notes contain certain covenants, and events of default and triggering events, respectively, which would require repayment of the obligations outstanding pursuant to such instruments. The obligations of the Company pursuant to the First Tranche Notes are (i) secured by all assets of the Company and all subsidiaries of the Company pursuant to the Security Agreement and Patent Security Agreement, dated August 14, 2024, August 14, 2024, Due to these embedded features within the First Tranche Notes, the Company elected to account for the First Tranche Notes at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the condensed consolidated statements of operations. Additionally the portion of changes in the fair value related to changes in credit risk are recorded to other comprehensive income in the consolidated statements of operations. To determine the initial carrying value of the Notes and the warrants issued to Anson under the First Tranche Notes (see Note 9 11 During the three nine September 30, 2024 September 30, 2024 three nine September 30, 2024, September 30, 2024

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
Note 8 - Commitments and Contingencies	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Sarah Herzog Memorial Hospital License Agreement The Company is required to make certain payments related to the development of NRX- 101 Licensed Product SHMH SHMH License Agreement Milestone Payments End of Phase I Clinical Trials of Licensed Product (completed) $ 100,000 End of Phase II Clinical Trials of Licensed Product (completed) $ 250,000 End of Phase III Clinical Trials of Licensed Product $ 250,000 First Commercial Sale of Licensed Product in U.S. $ 500,000 First Commercial Sale of Licensed Product in Europe $ 500,000 Annual Revenues Reach $100,000,000 $ 750,000 The milestone payments due above may three nine September 30, 2024 2023 Royalties A royalty in an amount equal to: (a) 1% of revenues from the sale of any product incorporating a Licensed Product when at least one not one not may not Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of 8.5% of the payments received by us from sub-licensees in connection with such sales. During the three nine September 30, 2023 Annual Maintenance Fee A fixed amount of $100,000 was paid on April 16, 2021 Exclusive License Agreement The Company has entered into a License Agreement with Apkarian Technologies to in-license US Patent 8,653,120 101 three nine September 30, 2024 2023 no Legal Proceedings The Company was a defendant in litigation filed by Streeterville in the Third Judicial District Court of Salt Lake County, Utah. See Note 7, no On July 29, 2024, On August 12, 2024, 7 September 30, 2024, no The Company is currently involved in and may not

Note 9 - Equity

Note 9 - Equity	9 Months Ended
Note 9 - Equity	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	9. Common Stock Reverse Stock Split On March 21, 2024, 1 March 28, 2024, Amendment ten one Effective April 1, 2024, one No one Preferred Stock Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has 50,000,000 shares of preferred stock with a par value of $0.001, of which 12,000,000 were designated Series A Convertible Preferred Stock ( "Series A Preferred" August 2023, March 2024 September 30, 2024 Common Stock Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has authorized 500,000,000 shares of Common Stock with a par value of $0.001. On January 2, 2024, From February 20, 2024 July 29, 2024, ATM Purchase Agreements April 15, 2024, August 14, 2023 ( Offering Agreemen Current Prospectus Supplement September 30, 2024, On February 29, 2024, February February 2024 February February 2024 4 2 1933, Securities Act February 2024 On February 27, 2024, February Representative February February 2024 February February February February 45 February February February 2024 February February 28, 2024, February 2024 February February 2024 March 5, 2024, February February February 27, 2024, February February March 6, 2024. February On April 18, 2024, April April April 2024 A pril Shares April 45 April April April 2024 April April 19, 2024, April April 2024 May 23, 2024, April April April 18, 2024, April April May 23, 2024. April On August 28, 2024, third Common Stock Warrants Substitute Warrants In connection with the Merger in 2021, "BRPA" Substitute Warrants 815, 820, The Company recognized a gain on the change in fair value of the Substitute Warrants for the three September 30, 2024 2023 nine September 30, 2024 2023 11 Assumed Public Warrants Prior to the Merger, the Company had 3,450,000 warrants outstanding (the “ Public Warrants one tenth five During the three nine September 30, 2024 2023 September 30, 2024 December 31, 2023 Assumed Private Placement Warrants Prior to the Merger, the Company had outstanding 136,250 Private Placement Warrants (the “ Private Placement Warrants not 815 40 15 not September 30, 2024 December 31, 2023 The Company recognized a gain on the change in fair value of the Private Placement Warrants for the three September 30, 2024 2023 nine September 30, 2024 2023 11 Investor Warrants As discussed above, on February 28, 2024, February February six five February On February 28, 2024, February six five On March 5, 2024 February On April 19, 2024, April April April six five April On May 23, 2024 April Alvogen Warrants In conjunction with the amended Alvogen licensing agreement discussed in Note 6, February 7, 2024 three may no may not 61 March 31, 2024. June 21, 2024, Anson Warrants The Anson Warrants, originally issued in the Purchase Agreement, are recognized as derivative liabilities in accordance with ASC 815. not August 14, 2024, five August 14, 2029. five August 14, 2024. September 30, 2023, 11 Weighted Average Weighted Aggregate Total Remaining Average Intrinsic Value Warrant Shares Term Exercise Price (in thousands) Outstanding as of December 31, 2023 3,321,499 3.91 $ 23.01 $ 180 Issued 718,348 Expired (5,510 ) Outstanding as of March 31, 2024 4,034,337 3.68 19.61 807 Issued 34,903 Outstanding as of June 30, 2024 4,069,240 3.44 $ 19.47 $ — Issued 1,349,305 Expired (90,909 ) Outstanding as of September 30, 2024 5,327,636 3.67 $ 13.39 $ —

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	9 Months Ended
Note 10 - Stock-based Compensation	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	10. 20 16 Prior to the Merger, NRx maintained its 2016 2016 2016 In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, based on the Exchange Ratio (of 0.316:1 Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate 289,542 shares of the Company’s Common Stock at an average exercise price of $51.00 per share. 2021 As of September 30, 2024 2021 2021 January 1, 2024 2021 January 1, 2022 January 1, 2031, December 28, 2023 first 2021 may 100% September 30, 2024 2021 2021 Option Awards The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company’s stock options for employees has been determined utilizing the “simplified” method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not NRX‑101, The Company issued no stock options during the three nine September 30, 2024 The following table summarizes the Company’s employee and non-employee stock option activity under the 2021 Number of shares Weighted average exercise price Weighted average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Outstanding as of December 31, 2023 264,983 $ 18.30 7.7 $ 75 Expired/Forfeited (89,546 ) Outstanding as of March 31, 2024 175,437 $ 18.60 8.4 $ 40 Expired/Forfeited (14,000 ) Outstanding as of June 30, 2024 161,437 $ 21.18 7.5 $ — Expired/Forfeited (29,604 ) Outstanding as of September 30, 2024 131,833 $ 21.01 7.4 $ — Options vested and exercisable as of September 30, 2024 109,399 $ 24.13 7.1 $ — Stock-based compensation expense related to stock options was $0.1 million and $0.4 million for the three nine September 30, 2024 At September 30, 2024 Restricted Stock Awards The following table presents the Company’s Restricted Stock Activity: Awards Weighted Average Grant Date Fair Value Balance as of December 31, 2023 (unvested) 124,166 $ 5.20 Vested (57,500 ) 4.64 Balance as of March 31, 2024 (unvested) 66,666 5.66 Vested — — Balance as of June 30, 2024 (unvested) 66,666 5.66 Vested (33,333 ) 2.08 Balance as of September 30, 2024 (unvested) 33,333 $ 5.66 On July 12, 2022, RSAs three On December 28, 2023, six September 4, 2023, Stock-based compensation expense related to RSAs was less than $0.1 million for the three nine September 30, 2024 Subsequent to September 30, 2024, not September 30, 2024. The following table summarizes the Company’s recognition of stock-based compensation for the following periods (in thousands): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 (Unaudited) Stock-based compensation expense General and administrative $ 82 $ 261 $ 365 $ 1,295 Research and development 22 90 78 295 Total stock-based compensation expense $ 104 $ 351 $ 443 $ 1,590

Note 11 - Fair Value Measuremen

Note 11 - Fair Value Measurements	9 Months Ended
Note 11 - Fair Value Measurements	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	11. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three nine September 30, 2024 2023 Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 1 3 September 30, 2024 December 31, 2023 Description Level September 30, 2024 December 31, 2023 Assets: (Unaudited) Money Market Account 1 $ 481 $ 3,874 Liabilities: Warrant liabilities (Note 9) 3 $ 1,902 $ 17 Convertible note payable - Streeterville (Note 7) 3 $ 3,050 $ 9,161 Convertible note payable - Anson (Note 7) 3 $ 2,985 $ — Convertible Note Payable - Streeterville The significant inputs used in the Monte Carlo simulation to measure the Streeterville note liability that is categorized within Level 3 September 30, September 30, 2024 2023 Stock price on valuation date * $ 2.60 Time to expiration * 0.59 Note market interest rate * 8.9 % Equity volatility * 90.0 % Volume volatility * 365.0 % Risk-free rate * 5.52 % Probability of default * 3.2 % *As of September 30, 2024, The following table sets forth a summary of the changes in the fair value of the Streeterville Note categorized within Level 3 Fair value of the Note as of December 31, 2023 $ 9,161 Conversions and repayments of principal and interest (cash) (2,300 ) Conversions and repayments of principal and interest (shares) (400 ) Fair value adjustment through earnings 318 Fair value of the Note as of March 31, 2024 6,779 Fair value adjustment through earnings 23 Default penalty 849 Fair value of the Note as of June 30, 2024 $ 7,651 Conversions and repayments of principal and interest (cash) (2,500 ) Fair value adjustment through earnings (2,101 ) Fair value of the Note as of September 30, 2024 $ 3,050 Convertible note payable - current portion $ 3,050 Convertible note payable, net of current portion $ — Fair value of the Note as of December 31, 2022 $ 10,525 Fair value adjustment through earnings 1,770 Fair value adjustment through accumulated other comprehensive loss (106 ) Fair value of the Note as of March 31, 2023 12,189 Conversions and repayments of principal and interest (cash) (88 ) Conversions and repayments of principal and interest (shares) (200 ) Fair value adjustment through earnings 663 Fair value adjustment through accumulated other comprehensive loss 128 Fair value of the Note as of June 30, 2023 $ 12,692 Conversions and repayments of principal and interest (cash) (2,200 ) Conversions and repayments of principal and interest (shares) (782 ) Fair value adjustment through earnings 359 Fair value of the Note as of September 30, 2023 $ 10,069 Convertible note payable - current portion $ 10,069 Convertible note payable, net of current portion $ — Convertible Note Payable - Anson The significant inputs used in the Monte Carlo simulation to measure the Anson note liability that is categorized within Level 3 September 30, 2024 Stock price on valuation date $ 1.69 Time to expiration 1.12 Note market interest rate 12.5% Equity volatility 122.0% Risk-free rate 3.94% Probability of default 33.6% The following table sets forth a summary of the changes in the fair value of the Anson Note categorized within Level 3 Fair value of the Note at issuance $ 2,941 Conversions and repayments of principal and interest (shares) (702 ) Fair value adjustment through earnings 746 Fair value of the Note as of September 30, 2024 $ 2,985 Convertible note payable - current portion $ — Convertible note payable, net of current portion $ 2,985 Warrant Liabilities The Company utilizes a Black-Scholes model approach to value its liability-classified warrants at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liabilities is determined using Level 3 no zero The weighted-average significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level 3 September 30, 2024 2023 Stock price on valuation date $ 1.69 $ 6.60 Exercise price per share $ 3.55 $ 115.00 Expected life 4.84 3.15 Volatility 129.8 % 175.1 % Risk-free rate 3.6 % 5.3 % Dividend yield 0.0 % 0.0 % Fair value of warrants $ 1.40 $ 7.93 A reconciliation of warrant liabilities is included below (in thousands): Balance as of December 31, 2023 $ 17 Loss upon re-measurement 9 Balance as of March 31, 2024 26 Gain upon re-measurement (18 ) Balance as of June 30, 2024 $ 8 Initial recognition of issuance of warrants 2,059 Gain upon re-measurement (165 ) Balance as of September 30, 2024 $ 1,902 Balance as of December 31, 2022 $ 37 Gain upon re-measurement (12 ) Balance as of March 31, 2023 25 Loss upon re-measurement 11 Balance as of June 30, 2023 $ 36 Loss upon re-measurement (26 ) Balance as of September 30, 2023 $ 10

Note 12 - Income Taxes

Note 12 - Income Taxes	9 Months Ended
Note 12 - Income Taxes	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. The Company recorded no provision or benefit for income tax expense for the nine September 30, 2024 2023 For all periods presented, the pretax losses incurred by the Company received no not The Company has no September 30, 2024

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	9 Months Ended
Note 13 - Related Party Transactions	Sep. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Glytech Agreement The Company licenses patents that are owned by Glytech, LLC (“ Glytech Glytech Agreement three September 30, 2024 2023 nine September 30, 2024 2023 The Fourth Amendment to the Glytech Agreement, effective as of December 31, 2020, not NRX‑100 NRX‑101. November 6, 2022 no March 31, 2024, ( Glytech Equity twenty 20 no twenty not March 31, 2024. Consulting Agreement with Dr. Jonathan Javitt The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major shareholder in the Company and is the Chairman of the Board of Directors. Therefore, the services provided to the Company are deemed to be a related party transaction. He served the Company on a full-time basis as CEO under an employment agreement with the Company until March 8, 2022 three September 30, 2024 2023 nine September 30, 2024 2023, On March 29, 2023, March 8, 2022 March 8, 2024 one Javitt Amendment 2023, may 2024 September 30, 2024 December 31, 2023 The Javitt Amendment also provides, subject to the approval of the Board of Directors, for a grant of 50,000 shares of restricted stock of the Company under the Company’s 2021 September 30, 2024 not The term “New Drug Application Date” means the date upon which the FDA files the Company’s new drug application for the Antidepressant Drug Regimen (as defined below) for review. The term “New Drug Approval Date” means date upon which the FDA has both approved the Company’s Antidepressant Drug Regimen and listed the Company’s Antidepressant Drug Regimen in the FDA’s “Orange Book”. The term “Antidepressant Drug Regimen” means NRX- 101, 100 Consulting Agreement with Zachary Javitt Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company’s CEO who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of less than $0.2 million and $0.1 million, respectively, during the three nine September 30, 2024 2023 Included in accounts payable were less than $0.1 million due to the above related parties as of September 30, 2024 December 31, 2023

Note 14 - Subsequent Event

Note 14 - Subsequent Event	9 Months Ended
Note 14 - Subsequent Event	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	14. Anson Convertible Note Pursuant to the Purchase Agreement, on October 10, 2024 ( seven In connection with the above offering, the Company engaged Placement Agent. Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of 7% of the gross proceeds the Company received in the Second Closing and incurred certain additional other issuance costs, for aggregate issuance costs of approximately $0.4 million. The Company also agreed to reimburse the Placement Agent at the Second Closing for expenses incurred, including disbursements of legal counsel, in an amount not Anson Conversion Notices From October 22, 2024 October 31, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. None 10b5 1 10b5 1 September 30, 2024 408 not 10b5–1 September 30, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP FASB ASC SEC not not may
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the fair value of the convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not may
Risks and Uncertainties [Policy Text Block]	Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not third
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments FASB ASC Topic 820, Fair Value Measurements ASC 820 The accounting guidance classifies fair value measurements in one three Level 1: Level 2: 1 Level 3: no 11
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not may, September 30, 2024 not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three may
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company accounts for revenue under FASB ASC Topic 606, Revenue for Contract with Customers ASC 606 not may may The Company enters into contractual arrangements that may 606, may The License Agreement (the “ License Agreement Alvogen 6 606. 606, 606, five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations within the contract; and v. recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five At contract inception, once the contract is determined to be within the scope of ASC 606, may not The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may not The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. The Company’s revenue arrangements may Milestone Payments first not Royalties Research Services 6
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development expense consists primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.
Deferred Charges, Policy [Policy Text Block]	Non-cancellable Contracts The Company may may
Debt, Policy [Policy Text Block]	Convertible Notes Payable and Fair Value Election As permitted under FASB ASC Topic 825, ASC 825 The Company estimates the fair value of its notes payable using a Monte Carlo simulation model, which uses as inputs the fair value of its Common Stock and estimates for the equity volatility of its Common Stock, the time to expiration (i.e., expected term) of the note, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the Company estimates its expected future equity volatility based on the historical volatility of its Common Stock price utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration to the redemption features embedded in the notes. The risk-free interest rate is determined based on the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Unless otherwise specified, the probability of default is estimated using Bloomberg’s Default Risk function which uses its financial information to calculate a default risk specific to the Company. At September 30, 2024,
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock award grants using the closing trading price of the Company’s Common Stock on the date of issuance. All stock-based compensation costs are recorded in general and administrative or research and development costs in the condensed consolidated statements of operations and comprehensive loss based upon the underlying individual’s role at the Company.
Derivatives, Policy [Policy Text Block]	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ASC 480 815, Derivatives and Hedging ASC 815 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not A change in any of the terms or conditions of warrants is accounted for as a modification. The accounting for incremental fair value of warrants is based on the specific facts and circumstances related to the modification which may
Stockholders' Equity, Policy [Policy Text Block]	Preferred Stock In accordance with ASC 480, not 815 40, Derivatives and Hedging Contracts in an Entity s Own Equity not not 815.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ASC 740 not not 740. not not
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share The Company applies the two two no two not Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if stock options, restricted stock awards and warrants were to vest and be exercised. Diluted earnings per share excludes, when applicable, the potential impact of stock options, Common Stock warrant shares, convertible notes, and other dilutive instruments because their effect would be anti-dilutive in the periods in which the Company incurs a net loss. The following outstanding shares of Common Stock equivalents were excluded from the computation of the diluted net loss per share attributable to Common Stock for the periods in which a net loss is presented because their effect would have been anti-dilutive. Nine months ended September 30, 2024 2023 Stock options 131,833 254,885 Restricted stock awards 33,333 66,667 Common stock warrants 5,327,636 3,302,159 Anson Note 3,236,280 — Convertible preferred stock — 300,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Not In November 2023, No. 2023‑07, 280 Improvements to Reportable Segment Disclosures (ASU 2023 07 2023 07 2023 07 December 15, 2023, December 15, 2024. In December 2023, 2023 09 740 mprovements to Income Tax Disclosures (ASU 2023 09 2023 09 2023 09 December 15, 2024.

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine months ended September 30, 2024 2023 Stock options 131,833 254,885 Restricted stock awards 33,333 66,667 Common stock warrants 5,327,636 3,302,159 Anson Note 3,236,280 — Convertible preferred stock — 300,000

Note 4 - Prepaid Expense and _2

Note 4 - Prepaid Expense and Other Current Assets (Tables)	9 Months Ended
Note 4 - Prepaid Expense and Other Current Assets (Tables)	Sep. 30, 2024
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	September 30, 2024 December 31, 2023 (Unaudited) Prepaid expense and other current assets: Prepaid insurance $ 1,185 $ 1,078 Prepaid clinical development costs 848 871 Other prepaid expense 421 334 Other current receivables 6 6 Total prepaid expense and other current assets $ 2,460 $ 2,289

Note 5 - Accrued and Other Cu_2

Note 5 - Accrued and Other Current Liabilities (Tables)	9 Months Ended
Note 5 - Accrued and Other Current Liabilities (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, 2024 December 31, 2023 (Unaudited) Accrued and other current liabilities: Refund liability (see Note 6) $ 4,715 $ — Professional services 3,573 2,686 Employee costs 324 835 Accrued research and development expense 592 1,112 Other accrued expense 240 81 Total accrued and other current liabilities $ 9,444 $ 4,714

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	9 Months Ended
Note 8 - Commitments and Contingencies (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Milestone Payments [Table Text Block]	End of Phase I Clinical Trials of Licensed Product (completed) $ 100,000 End of Phase II Clinical Trials of Licensed Product (completed) $ 250,000 End of Phase III Clinical Trials of Licensed Product $ 250,000 First Commercial Sale of Licensed Product in U.S. $ 500,000 First Commercial Sale of Licensed Product in Europe $ 500,000 Annual Revenues Reach $100,000,000 $ 750,000

Note 9 - Equity (Tables)

Note 9 - Equity (Tables)	9 Months Ended
Note 9 - Equity (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted Average Weighted Aggregate Total Remaining Average Intrinsic Value Warrant Shares Term Exercise Price (in thousands) Outstanding as of December 31, 2023 3,321,499 3.91 $ 23.01 $ 180 Issued 718,348 Expired (5,510 ) Outstanding as of March 31, 2024 4,034,337 3.68 19.61 807 Issued 34,903 Outstanding as of June 30, 2024 4,069,240 3.44 $ 19.47 $ — Issued 1,349,305 Expired (90,909 ) Outstanding as of September 30, 2024 5,327,636 3.67 $ 13.39 $ —

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	9 Months Ended
Note 10 - Stock-based Compensation (Tables)	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of shares Weighted average exercise price Weighted average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Outstanding as of December 31, 2023 264,983 $ 18.30 7.7 $ 75 Expired/Forfeited (89,546 ) Outstanding as of March 31, 2024 175,437 $ 18.60 8.4 $ 40 Expired/Forfeited (14,000 ) Outstanding as of June 30, 2024 161,437 $ 21.18 7.5 $ — Expired/Forfeited (29,604 ) Outstanding as of September 30, 2024 131,833 $ 21.01 7.4 $ — Options vested and exercisable as of September 30, 2024 109,399 $ 24.13 7.1 $ —
Nonvested Restricted Stock Shares Activity [Table Text Block]	Awards Weighted Average Grant Date Fair Value Balance as of December 31, 2023 (unvested) 124,166 $ 5.20 Vested (57,500 ) 4.64 Balance as of March 31, 2024 (unvested) 66,666 5.66 Vested — — Balance as of June 30, 2024 (unvested) 66,666 5.66 Vested (33,333 ) 2.08 Balance as of September 30, 2024 (unvested) 33,333 $ 5.66
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 (Unaudited) Stock-based compensation expense General and administrative $ 82 $ 261 $ 365 $ 1,295 Research and development 22 90 78 295 Total stock-based compensation expense $ 104 $ 351 $ 443 $ 1,590

Note 11 - Fair Value Measurem_2

Note 11 - Fair Value Measurements (Tables)	9 Months Ended
Note 11 - Fair Value Measurements (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Description Level September 30, 2024 December 31, 2023 Assets: (Unaudited) Money Market Account 1 $ 481 $ 3,874 Liabilities: Warrant liabilities (Note 9) 3 $ 1,902 $ 17 Convertible note payable - Streeterville (Note 7) 3 $ 3,050 $ 9,161 Convertible note payable - Anson (Note 7) 3 $ 2,985 $ —
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30, September 30, 2024 2023 Stock price on valuation date * $ 2.60 Time to expiration * 0.59 Note market interest rate * 8.9 % Equity volatility * 90.0 % Volume volatility * 365.0 % Risk-free rate * 5.52 % Probability of default * 3.2 % September 30, 2024 Stock price on valuation date $ 1.69 Time to expiration 1.12 Note market interest rate 12.5% Equity volatility 122.0% Risk-free rate 3.94% Probability of default 33.6% September 30, 2024 2023 Stock price on valuation date $ 1.69 $ 6.60 Exercise price per share $ 3.55 $ 115.00 Expected life 4.84 3.15 Volatility 129.8 % 175.1 % Risk-free rate 3.6 % 5.3 % Dividend yield 0.0 % 0.0 % Fair value of warrants $ 1.40 $ 7.93
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value of the Note as of December 31, 2023 $ 9,161 Conversions and repayments of principal and interest (cash) (2,300 ) Conversions and repayments of principal and interest (shares) (400 ) Fair value adjustment through earnings 318 Fair value of the Note as of March 31, 2024 6,779 Fair value adjustment through earnings 23 Default penalty 849 Fair value of the Note as of June 30, 2024 $ 7,651 Conversions and repayments of principal and interest (cash) (2,500 ) Fair value adjustment through earnings (2,101 ) Fair value of the Note as of September 30, 2024 $ 3,050 Convertible note payable - current portion $ 3,050 Convertible note payable, net of current portion $ — Fair value of the Note as of December 31, 2022 $ 10,525 Fair value adjustment through earnings 1,770 Fair value adjustment through accumulated other comprehensive loss (106 ) Fair value of the Note as of March 31, 2023 12,189 Conversions and repayments of principal and interest (cash) (88 ) Conversions and repayments of principal and interest (shares) (200 ) Fair value adjustment through earnings 663 Fair value adjustment through accumulated other comprehensive loss 128 Fair value of the Note as of June 30, 2023 $ 12,692 Conversions and repayments of principal and interest (cash) (2,200 ) Conversions and repayments of principal and interest (shares) (782 ) Fair value adjustment through earnings 359 Fair value of the Note as of September 30, 2023 $ 10,069 Convertible note payable - current portion $ 10,069 Convertible note payable, net of current portion $ — Fair value of the Note at issuance $ 2,941 Conversions and repayments of principal and interest (shares) (702 ) Fair value adjustment through earnings 746 Fair value of the Note as of September 30, 2024 $ 2,985 Convertible note payable - current portion $ — Convertible note payable, net of current portion $ 2,985 Balance as of December 31, 2023 $ 17 Loss upon re-measurement 9 Balance as of March 31, 2024 26 Gain upon re-measurement (18 ) Balance as of June 30, 2024 $ 8 Initial recognition of issuance of warrants 2,059 Gain upon re-measurement (165 ) Balance as of September 30, 2024 $ 1,902 Balance as of December 31, 2022 $ 37 Gain upon re-measurement (12 ) Balance as of March 31, 2023 25 Loss upon re-measurement 11 Balance as of June 30, 2023 $ 36 Loss upon re-measurement (26 ) Balance as of September 30, 2023 $ 10

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) $ in Thousands		2 Months Ended	9 Months Ended
Note 2 - Going Concern (Details Textual) $ in Thousands	Aug. 14, 2024 USD ($)	Oct. 14, 2024 USD ($)	Sep. 30, 2024 USD ($)	Oct. 10, 2024 USD ($)	Aug. 12, 2024 USD ($)	Dec. 31, 2023 USD ($)
Revenue from Contract with Customer, Excluding Assessed Tax			$ 0
Cash and Cash Equivalents, at Carrying Value			$ 1,646			$ 4,595
Anson [Member]
Proceeds from Debt, Net of Issuance Costs	$ 4,500
Proceeds from Issuance of Debt		$ 10,870
Anson Convertible Notes [Member]
Debt Instrument, Face Amount					$ 16,300
Debt Instrument, Number of Tranches					3
Debt Instrument, Face Amount, Individual Tranches					$ 5,435
Anson First Tranche Notes [Member]
Debt Instrument, Face Amount	5,435
Proceeds from Debt, Net of Issuance Costs	$ 4,500
Anson Second Tranche Notes [Member] \| Subsequent Event [Member]
Debt Instrument, Face Amount		$ 5,435		$ 5,435

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Millions		1 Months Ended
	Apr. 01, 2024 $ / shares shares	Apr. 30, 2024 shares	Sep. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.001		$ 0.001	$ 0.001
Stock Issued During Period, Shares, Reverse Stock Splits (in shares) \| shares	0	73,040
Money Market Funds [Member]
Cash, Uninsured Amount \| $			$ 1.2
Stockholders' Equity, Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	131,833	254,885
Restricted Stock [Member]
Antidilutive securities (in shares)	33,333	66,667
Warrant [Member]
Antidilutive securities (in shares)	5,327,636	3,302,159
Anson Note [Member]
Antidilutive securities (in shares)	3,236,280	0
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	0	300,000

Note 4 - Prepaid Expense and _3

Note 4 - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid insurance	$ 1,185	$ 1,078
Prepaid clinical development costs	848	871
Other prepaid expense	421	334
Other current receivables	6	6
Total prepaid expense and other current assets	$ 2,460	$ 2,289

Note 5 - Accrued and Other Cu_3

Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Refund liability (see Note 6)	$ 4,715	$ 0
Professional services	3,573	2,686
Employee costs	324	835
Accrued research and development expense	592	1,112
Other accrued expense	240	81
Total accrued and other current liabilities	$ 9,444	$ 4,714

Note 6 - Alvogen Licensing Ag_2

Note 6 - Alvogen Licensing Agreement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 29, 2024	Sep. 30, 2024	Feb. 07, 2024	Dec. 31, 2023	Jun. 02, 2023
Customer Refund Liability, Current		$ 4,715		$ 0
Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 4
Warrants and Rights Outstanding, Term (Year)			3 years
Alvogen Licensing Agreement [Member]
License Agreement, Initial Payment	$ 4,000				$ 9,000
License Agreement, Accelerating Payment	$ 5,000
Customer Refund Liability, Current		4,700
Stock Subscriptions Receivable, Write Off		$ 1,300
Alvogen Licensing Agreement [Member] \| Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4
Warrants and Rights Outstanding, Term (Year)	3 years
Warrants and Rights Outstanding	$ 1,300

Note 7 - Debt (Details Textual)

Note 7 - Debt (Details Textual)												3 Months Ended		9 Months Ended
Note 7 - Debt (Details Textual)	Oct. 31, 2024 USD ($)	Oct. 10, 2024 USD ($)	Aug. 15, 2024 USD ($)	Aug. 14, 2024 USD ($) $ / shares shares	Aug. 12, 2024 USD ($)	Jul. 29, 2024	Apr. 24, 2024 USD ($)	Feb. 09, 2024 USD ($)	Jul. 10, 2023 USD ($)	Jul. 07, 2023 USD ($)	Nov. 04, 2022 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Loss on Contract Termination for Default												$ 0	$ 0	$ 849,000	$ 0
Debt Issuance Costs														521,000	0
Gain (Loss) on Convertible Debt Redemption												(127,000)	0	(127,000)	0
Anson Warrants [Member]
Class of Warrant or Right, Securities Called by Warrants or Rights, Percentage of Principal Divided by VWAP					50%
Warrants and Rights Outstanding				$ 2,100,000
Anson Warrants Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares				1,349,305
Warrants and Rights Outstanding				$ 2,100,000								1,900,000		1,900,000
Streetervile Complaint [Member]
Loss Contingency, Damages Sought, Value							$ 6,537,027
Stockholders Equity Note Spinoff Transaction, Percentage						49%
Litigation Settlement, Payment Installment One					$ 2,500,000
Litigation Settlement, Payment Installment Two					3,050,000
Payments for Legal Settlements			$ 2,500,000
Streetervile Complaint [Member] \| Subsequent Event [Member]
Payments for Legal Settlements	$ 3,050,000	$ 3,050,000
Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Converted Instrument, Amount														1,102,000	982,000
Streeterville Convertible Note [Member]
Debt Instrument, Interest Rate, Stated Percentage											9%
Debt Instrument, Face Amount											$ 11,000,000
Debt Instrument, Term (Month)											18 months
Debt Instrument, Unamortized Discount											$ 1,000,000
Proceeds from Issuance of Debt											$ 10,000,000
Debt Instrument, Prepayment Percentage											110%
Debt Instrument, Redemption Amount											$ 1,000,000
Debt Instrument, Redemption Price, Percentage											10%
Debt Instrument, Redemption Conversion Price, Percentage											85%
Debt Instrument, Conditional Default Interest Rate											18%
Debt Instrument, Convertible, Maximum Percentage of Equity Issuable											9.99%
Repayments of Debt												2,100,000	1,700,000	4,300,000	1,800,000
Liabilities, Fair Value Adjustment												2,100,000	400,000	1,800,000	2,800,000
Interest Expense, Debt												400,000	500,000	500,000	700,000
Redemption Premium												200,000		200,000
Loss on Contract Termination for Default												800,000		800,000
Long-Term Debt, Gross												3,000,000		3,000,000		$ 8,300,000
Streeterville Convertible Note [Member] \| Interest Repayment [Member]
Debt Conversion, Converted Instrument, Amount												100,000	100,000	100,000	100,000
Streeterville Convertible Note [Member] \| Principal Repayment [Member]
Debt Conversion, Converted Instrument, Amount												$ 300,000	$ 900,000	300,000	$ 900,000
Streeterville Convertible Note Amendment 2 [Member]
Repayments of Debt									$ 1,800,000
Debt Instrument, Periodic Payment										$ 400,000
Streeterville Convertible Note Amendment 2 [Member] \| Maximum [Member]
Debt Instrument, Periodic Payment										$ 1,000,000
Streeterville Convertible Note Amendment 3 [Member]
Repayments of Debt								$ 1,100,000
Debt Instrument, Periodic Payment								$ 400,000
Anson Convertible Notes [Member]
Debt Instrument, Face Amount					16,300,000
Long-Term Debt, Gross					$ 15,000,000
Debt Instrument, Number of Tranches					3
Placement Agent Fee, Percent of Gross Proceeds					7%
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares												458,553
Anson Convertible Notes [Member] \| Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Converted Instrument, Amount												$ 700,000		$ 700,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares														458,553
Gain (Loss) on Convertible Debt Redemption												100,000		$ 100,000
Anson First Tranche Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage				6%
Debt Instrument, Face Amount				$ 5,435,000
Debt Instrument, Term (Month)				15 months
Debt Instrument, Unamortized Discount				$ 485,000
Liabilities, Fair Value Adjustment												700,000		700,000
Long-Term Debt, Gross				$ 2,900,000								4,700,000		4,700,000
Debt Instrument, Original Issuance Discount				8%
Debt Issuance Costs				$ 521,000
Proceeds from Debt, Net of Issuance Costs				$ 4,500,000
Debt Instrument, Interest Rate in Event of Default				10%
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares				$ 2.4168
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				92%
Interest Payable												$ 100,000		$ 100,000
Debt Instrument, Interest Rate, Effective Percentage												69.30%		69.30%
Anson First Tranche Notes [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares				$ 0.38

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)					3 Months Ended		9 Months Ended
	Aug. 12, 2024	Jul. 29, 2024	Apr. 24, 2024	Apr. 16, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Apr. 16, 2022
Streetervile Complaint [Member]
Loss Contingency, Damages Sought, Value			$ 6,537,027
Stockholders Equity Note Spinoff Transaction, Percentage		49%
Streetervile Complaint [Member] \| Convertible Debt [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 5,600,000
Sarah Herzog Memorial Hospital License Agreement [Member]
License Agreements, Milestone Payments, Conditional Reduction Percentage									25%
License Agreement, Milestone Payment					$ 0	$ 0	$ 0	$ 0
Payments for Royalties						$ 0		$ 0
Payment for License Agreement, Maintenance Fee				$ 100,000
License Agreement, Maintenance Fee										$ 150,000
Sarah Herzog Memorial Hospital License Agreement [Member] \| Maximum [Member]
Royalty Percentage					8.50%		8.50%
Sarah Herzog Memorial Hospital License Agreement [Member] \| Products Covered By Licensed Patents [Member]
Royalty Percentage					1%		1%
Sarah Herzog Memorial Hospital License Agreement [Member] \| Products Covered by Valid Claims [Member]
Royalty Percentage					2.50%		2.50%

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details) - Sarah Herzog Memorial Hospital License Agreement [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Milestone payment	$ 0	$ 0	$ 0	$ 0
End of Phase I Clinical Trials of Licensed Product [Member]
Milestone payment			100,000
End of Phase II Clinical Trials of Licensed Product [Member]
Milestone payment			250,000
End of Phase III Clinical Trials of Licensed Product [Member]
Milestone payment			250,000
First Commercial Sale of Licensed Product in U.S. [Member]
Milestone payment			500,000
First Commercial Sale of Licensed Product in Europe [Member]
Milestone payment			500,000
Annual Revenue Threshold [Member]
Milestone payment			$ 750,000

Note 9 - Equity (Details Textua

Note 9 - Equity (Details Textual)														1 Months Ended			3 Months Ended				5 Months Ended	9 Months Ended
Note 9 - Equity (Details Textual)	Aug. 28, 2024 USD ($) shares	May 23, 2024 USD ($) $ / shares shares	Apr. 19, 2024 USD ($) shares	Apr. 18, 2024 USD ($) $ / shares shares	Apr. 01, 2024 $ / shares shares	Mar. 06, 2024 USD ($)	Mar. 05, 2024 USD ($) shares	Feb. 29, 2024 USD ($) $ / shares shares	Feb. 28, 2024 USD ($) $ / shares shares	Feb. 27, 2024 $ / shares shares	Feb. 07, 2024 USD ($) $ / shares shares	Jan. 02, 2024 USD ($) shares	Aug. 14, 2023 shares	Apr. 30, 2024 shares	Mar. 31, 2024 shares	Aug. 31, 2023 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares	Jul. 29, 2024 $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Aug. 14, 2024 USD ($) $ / shares shares	Mar. 28, 2024 shares	Dec. 31, 2023 $ / shares shares	May 24, 2021 $ / shares shares
Common Stock, Shares, Issued (in shares)					9,600,000												11,373,246					11,373,246			95,700,000	8,391,940
Common Stock, Shares, Outstanding (in shares)					9,600,000												11,373,246					11,373,246			95,700,000	8,391,940
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)					0									73,040
Preferred Stock, Shares Authorized (in shares)																	50,000,000					50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares																	$ 0.001					$ 0.001
Stock Issued During Period, Shares, New Issues (in shares)																						1,700,000
Common Stock, Shares Authorized (in shares)																	500,000,000					500,000,000				500,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares					$ 0.001												$ 0.001					$ 0.001				$ 0.001
Proceeds from Issuance of Private Placement \| $																						$ 1,027,000	$ 8,122,000
Stock Issued During Period, Shares, Issued for Services (in shares)	20,000
Stock Issued During Period, Value, Issued for Services \| $	$ 0.1																$ 37,000
Class of Warrant or Right, Outstanding (in shares)															4,034,337		5,327,636	4,069,240	4,034,337			5,327,636				3,321,499
Fair Value Adjustment of Warrants \| $																	$ (165,000)			$ (26,000)		$ (174,000)	(27,000)
Adjustments to Additional Paid in Capital, Warrant Issued \| $																			$ 0
February Warrants [Member]
Warrants and Rights Outstanding, Term (Year)									5 years
Adjustments to Additional Paid in Capital, Warrant Issued \| $									$ 500,000
February Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input									3.59
February Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input									3.8
February Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input									5
February Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input									1.781
February Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input									0.0426
February Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input									0
Substitute Warrants [Member]
Fair Value Adjustment of Warrants \| $																	$ 0	$ 100,000				$ 100,000	$ 100,000
Substitute Warrants [Member] \| Neuro Rx [Member]
Foreign Currency Exchange Rate, Remeasurement																											0.316
Class of Warrant or Right, Outstanding (in shares)																											3,792,970
Public Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	344,886					344,886				344,886	345,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																											$ 115
Class of Warrant or Right, Outstanding (in shares)																	3,448,856					3,448,856				3,448,856	3,450,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																											0.1
Class of Warrant or Right, Exercised During Period (in shares)																	0			0		0	0
Private Placement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	13,625					13,625
Class of Warrant or Right, Outstanding (in shares)																	136,250					136,250
Fair Value Adjustment of Warrants \| $																	$ 100,000			$ 100,000		$ 100,000	$ 100,000
February Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									25,000
Warrants and Rights Outstanding, Term (Year)									5 years
Adjustments to Additional Paid in Capital, Warrant Issued \| $									$ 100,000
February Underwriter Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input									3.05
February Underwriter Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input									3.3
February Underwriter Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input									5
February Underwriter Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input									1.781
February Underwriter Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input									0.0426
February Underwriter Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input									0
Underwriter Overallotment Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							3,750
Adjustments to Additional Paid in Capital, Warrant Issued \| $			$ 100,000				$ 100,000
Underwriter Overallotment Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input		3.62	3.04				3.05
Underwriter Overallotment Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input		3.63	3.63				3.3
Underwriter Overallotment Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input		5	5				5
Underwriter Overallotment Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		1.781	1.781				1.781
Underwriter Overallotment Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0.0452	0.0466				0.0412
Underwriter Overallotment Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0	0				0
Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares											$ 4
Warrants and Rights Outstanding, Term (Year)											3 years
Adjustments to Additional Paid in Capital, Warrant Issued \| $											$ 1,300,000
Class of Warrant or Right, Beneficial Ownership Limitation											4.99%
Alvogen and Lotus Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input											4.1
Alvogen and Lotus Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input											4
Alvogen and Lotus Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input											3
Alvogen and Lotus Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input											1.38
Alvogen and Lotus Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input											0.042
Alvogen and Lotus Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input											0
Anson Warrants Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																								1,349,305
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																								$ 2.4168
Warrants and Rights Outstanding, Term (Year)																								5 years
Warrants and Rights Outstanding \| $																	1,900,000					$ 1,900,000		$ 2,100,000
Anson Warrants Tranche One [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																								1.86
Anson Warrants Tranche One [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																								2.42
Anson Warrants Tranche One [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																								5
Anson Warrants Tranche One [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																								1.22
Anson Warrants Tranche One [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																								0.0367
Anson Warrants Tranche One [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																								0
Maximum [Member] \| Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Beneficial Ownership Limitation											9.99%
ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)													4,900,000								385,515
Stock Issued During Period, Value, New Issues \| $																	$ 219,000	$ 1,228,000	179,000
ATM Offering [Member] \| Minimum [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares																					$ 2.42
ATM Offering [Member] \| Maximum [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares																					$ 7.1
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)								270,000	270,000
Stock Issued During Period, Value, New Issues \| $																			1,027,000
Private Placement, Premium Percentage								26.70%
Proceeds from Issuance of Private Placement \| $								$ 1,000,000
Private Placement [Member] \| February Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								270,000	270,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 3.8	$ 3.8
February Underwriting Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)										500,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares										$ 2.76
Share Price (in dollars per share) \| $ / shares										$ 3
Proceeds from Issuance or Sale of Equity \| $									$ 1,300,000
Payments of Stock Issuance Costs \| $									$ 400,000
February Overallotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)										75,000
Share Price (in dollars per share) \| $ / shares										$ 3
Proceeds from Issuance or Sale of Equity \| $						$ 200,000
Payments of Stock Issuance Costs \| $						$ 200,000
April Underwriter Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				607,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares				$ 3.3
April Overallotment Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		91,050		91,050
Shares Issued, Price Per Share (in dollars per share) \| $ / shares		$ 3.3
Proceeds from Issuance or Sale of Equity \| $		$ 200,000
Payments of Stock Issuance Costs \| $		$ 100,000
April 2024 Offering [Member]
Payments of Stock Issuance Costs \| $				$ 400,000
Proceeds from Issuance of Common Stock \| $				$ 1,600,000
April 2024 Offering [Member] \| April Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		4,553	30,350
Warrants and Rights Outstanding, Term (Year)			6 years
April 2024 Offering [Member] \| April Overallotment Warrants [Member]
Warrants and Rights Outstanding, Term (Year)			5 years
Convertible Debt [Member] \| Conversion of Debt to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)												143,648
Debt Conversion, Converted Instrument, Amount \| $												$ 400,000
Preferred Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)																		0
Stock Issued During Period, Shares, Issued for Services (in shares)																	0
Stock Issued During Period, Value, Issued for Services \| $																	$ 0
Adjustments to Additional Paid in Capital, Warrant Issued \| $																			$ 0
Preferred Stock [Member] \| ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)																	0	0	0
Stock Issued During Period, Value, New Issues \| $																	$ 0	$ 0	$ 0
Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)																			0
Stock Issued During Period, Value, New Issues \| $																			$ 0
Conversion of Series A Preferred Stock to Preferred Stock [Member] \| Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)															300,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)																	12,000,000					12,000,000
Stock Issued During Period, Shares, New Issues (in shares)																3,000,000
Stock Issued During Period, Value, New Issues \| $																$ 1,200,000
Preferred Stock, Shares Issued (in shares)																	0					0
Preferred Stock, Shares Outstanding (in shares)																	0					0
Series A Preferred Stock [Member] \| Preferred Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)																		0
Conversion of Stock, Shares Converted (in shares)																			3,000,000
Stock Issued During Period, Shares, Issued for Services (in shares)																	0
Stock Issued During Period, Value, Issued for Services \| $																	$ 0
Adjustments to Additional Paid in Capital, Warrant Issued \| $																			$ 0
Series A Preferred Stock [Member] \| Preferred Stock [Member] \| ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)																	0	0	0
Stock Issued During Period, Value, New Issues \| $																	$ 0	$ 0	$ 0
Series A Preferred Stock [Member] \| Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)																			0
Stock Issued During Period, Value, New Issues \| $																			$ 0
Series A Preferred Stock [Member] \| Conversion of Series A Preferred Stock to Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)															3,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio					10

Note 9 - Equity - Schedule of W

Note 9 - Equity - Schedule of Warrants (Details) - USD ($)	3 Months Ended			12 Months Ended
Note 9 - Equity - Schedule of Warrants (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Outstanding, balance (in shares)	4,069,240	4,034,337	3,321,499
Outstanding, weighted average remaining contractual term (Year)	3 years 8 months 1 day	3 years 5 months 8 days	3 years 8 months 4 days	3 years 10 months 28 days
Outstanding, weighted average exercise price (in dollars per share)	$ 19.47	$ 19.61	$ 23.01
Outstanding, aggregate intrinsic value	$ 0	$ 0	$ 807,000	$ 180,000
Issued (in shares)	1,349,305	34,903	718,348
Expired (in shares)	(90,909)		(5,510)
Outstanding, balance (in shares)	5,327,636	4,069,240	4,034,337	3,321,499
Outstanding, weighted average exercise price (in dollars per share)	$ 13.39	$ 19.47	$ 19.61	$ 23.01

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended
	Jan. 01, 2024 shares	Dec. 28, 2023 USD ($) $ / shares shares	Jul. 12, 2022 shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Jun. 30, 2024 $ / shares shares	Mar. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Jan. 01, 2022	May 24, 2021 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				131,833		131,833		161,437	175,437	264,983
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares				$ 21.01		$ 21.01		$ 21.18	$ 18.6	$ 18.3
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				0		0
Share-Based Payment Arrangement, Expense \| $				$ 104	$ 351	$ 443	$ 1,590
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0%
Share-Based Payment Arrangement, Expense \| $				100		$ 400
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $				100		$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						10 months 24 days
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		57,500
Share-Based Payment Arrangement, Expense \| $				100		$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $				$ 0		$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares		$ 4.6
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value \| $		$ 300
Restricted Stock [Member] \| Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)			3 years
The 2016 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				347,200		347,200
The 2016 Omnibus Incentive Plan [Member] \| Neuro Rx [Member]
Foreign Currency Exchange Rate, Remeasurement												0.316
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)												289,542
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares												$ 51
The 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				955,281		955,281
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	83,920	200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares											1%
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)						585,099
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				370,182		370,182

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation - Schedule of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Outstanding, balance (in shares)	161,437	175,437	264,983	264,983	264,983
Outstanding, weighted average exercise price (in dollars per share)	$ 21.18	$ 18.6	$ 18.3	$ 18.3	$ 18.3
Outstanding, weighted average remaining contractual term (Year)	7 years 4 months 24 days	7 years 6 months	8 years 4 months 24 days			7 years 8 months 12 days
Outstanding, aggregate intrinsic value	$ 0	$ 0	$ 40	$ 0	$ 0	$ 75
Expired/Forfeited (in shares)	(29,604)		(89,546)	(14,000)
Outstanding, balance (in shares)	131,833	161,437	175,437	161,437	131,833	264,983
Outstanding, weighted average exercise price (in dollars per share)	$ 21.01	$ 21.18	$ 18.6	$ 21.18	$ 21.01	$ 18.3
Options vested and exercisable (in shares)	109,399				109,399
Options vested and exercisable, weighted average exercise price (in dollars per share)	$ 24.13				$ 24.13
Options vested and exercisable, weighted average remaining contractual term (Year)					7 years 1 month 6 days
Options vested and exercisable, aggregate intrinsic value	$ 0				$ 0

Note 10 - Stock-based Compens_5

Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Balance (unvested) (in shares)	66,666	66,666	124,166
Unvested, weighted average grant date fair value (in dollars per share)	$ 5.66	$ 5.66	$ 5.66	$ 5.2
Vested (in shares)	(33,333)	0	(57,500)
Vested, weighted average grant date fair value (in dollars per share)	$ 2.08	$ 0	$ 4.64
Balance (unvested) (in shares)	33,333	66,666	66,666

Note 10 - Stock-based Compens_6

Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-based compensation expense	$ 104	$ 351	$ 443	$ 1,590
General and Administrative Expense [Member]
Stock-based compensation expense	82	261	365	1,295
Research and Development Expense [Member]
Stock-based compensation expense	$ 22	$ 90	$ 78	$ 295

Note 11 - Fair Value Measurem_3

Note 11 - Fair Value Measurements (Details Textual) $ in Millions	Sep. 30, 2024 USD ($)
Streeterville Convertible Note [Member]
Convertible Debt, Fair Value Disclosures	$ 3.1

Note 11 - Fair Value Measurem_4

Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Inputs, Level 1 [Member]
Money Market Account	$ 481	$ 3,874
Fair Value, Inputs, Level 3 [Member]
Warrant liabilities (Note 9)	1,902	17
Convertible note payable - Streeterville (Note 7)	3,050	9,161
Convertible note payable - Anson (Note 7)	$ 2,985	$ 0

Note 11 - Fair Value Measurem_5

Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)	Sep. 30, 2024 $ / shares	Sep. 30, 2023 $ / shares
Warrants [Member]
Fair value of warrants (in dollars per share)	$ 1.4	$ 7.93
Measurement Input, Share Price [Member] \| Streeterville Convertible Note [Member]
Measurement input	2.6
Measurement Input, Share Price [Member] \| Anson Convertible Notes [Member]
Measurement input	1.69
Measurement Input, Share Price [Member] \| Warrants [Member]
Warrant measurement input	1.69	6.6
Measurement Input, Expected Term [Member] \| Streeterville Convertible Note [Member]
Measurement input	0.59
Measurement Input, Expected Term [Member] \| Anson Convertible Notes [Member]
Measurement input	1.12
Measurement Input, Expected Term [Member] \| Warrants [Member]
Warrant measurement input	4.84	3.15
Measurement Input, Market Rate [Member[ \| Streeterville Convertible Note [Member]
Measurement input	0.089
Measurement Input, Market Rate [Member[ \| Anson Convertible Notes [Member]
Measurement input	0.125
Measurement Input, Price Volatility [Member] \| Streeterville Convertible Note [Member]
Measurement input	0.90
Measurement Input, Price Volatility [Member] \| Anson Convertible Notes [Member]
Measurement input	1.22
Measurement Input, Price Volatility [Member] \| Warrants [Member]
Warrant measurement input	1.298	1.751
Measurement Input, Risk Free Interest Rate [Member] \| Streeterville Convertible Note [Member]
Measurement input	0.0552
Measurement Input, Risk Free Interest Rate [Member] \| Anson Convertible Notes [Member]
Measurement input	0.0394
Measurement Input, Risk Free Interest Rate [Member] \| Warrants [Member]
Warrant measurement input	0.036	0.053
Measurement Input, Probability of Default [Member] \| Streeterville Convertible Note [Member]
Measurement input	0.032
Measurement Input, Probability of Default [Member] \| Anson Convertible Notes [Member]
Measurement input	0.336
Measurement Input, Volume Volatility [Member] \| Streeterville Convertible Note [Member]
Measurement input	3.65
Measurement Input, Exercise Price [Member] \| Warrants [Member]
Warrant measurement input	3.55	115
Measurement Input, Expected Dividend Rate [Member] \| Warrants [Member]
Warrant measurement input	0	0

Note 11 - Fair Value Measurem_6

Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details) - USD ($)	2 Months Ended	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Anson Convertible Notes [Member]
Convertible note payable - current portion	$ 0	$ 0
Convertible note payable, net of current portion	2,985	2,985
Streeterville Convertible Note [Member]
Convertible note payable - current portion	3,050,000	3,050,000			$ 10,069,000
Convertible note payable, net of current portion	0	0			0
Streeterville Convertible Note [Member]
Fair value of the Note as of December 31, 2023		7,651,000	$ 6,779,000	$ 9,161,000	12,692,000	$ 12,189,000	$ 10,525,000
Conversions and repayments of principal and interest (cash)		(2,500,000)	849,000	(2,300,000)	(2,200,000)		(88,000)
Conversions and repayments of principal and interest (shares)			(400,000)		(782,000)	(200,000)
Fair value adjustment through earnings		(2,101,000)	23,000	318,000	359,000	663,000	1,770,000
Default penalty		(2,500,000)	849,000	(2,300,000)	(2,200,000)		(88,000)
Fair value adjustment through accumulated other comprehensive loss						128,000	(106,000)
Fair value of the Note as of March 31, 2024	3,050,000	3,050,000	7,651,000	6,779,000	10,069,000	12,692,000	12,189,000
Anson Convertible Notes [Member]
Fair value of the Note as of December 31, 2023	2,941
Conversions and repayments of principal and interest (shares)	(702)
Fair value adjustment through earnings	746
Fair value of the Note as of March 31, 2024	2,985	2,985
Warrants [Member]
Fair value of the Note as of December 31, 2023		8,000	26,000	17,000	36,000	25,000	37,000
Fair value adjustment through earnings		(165,000)	(18,000)	9,000	(26,000)	11,000	(12,000)
Fair value of the Note as of March 31, 2024	$ 1,902,000	1,902,000	$ 8,000	$ 26,000	$ 10,000	$ 36,000	$ 25,000
Initial recognition of issuance of warrants		$ 2,059,000

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Tax Expense (Benefit)	$ 0	$ 0

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Mar. 29, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Nov. 06, 2022
Accounts Payable, Current		$ 4,866		$ 4,866		$ 4,632
Related Party [Member]
Accounts Payable, Current		100		100		100
Glytech License Agreement [Member]
Related Party Transaction, Amounts of Transaction		0	$ 100	300	$ 200
Glytech License Agreement [Member] \| NRX Pharmaceuticals, Inc [Member] \| Minimum [Member]
Investment Owned, Fair Value							$ 50,000
Consultation Agreement with Dr. Jonathan Javitt [Member]
Related Party Transaction, Amounts of Transaction		200	200	200	700
Consultation Agreement with Zachary Javitt [Member]
Related Party Transaction, Amounts of Transaction		200	$ 100	200	$ 100
Consulting Agreement, Annual Payment	$ 600
Consulting Agreement, Monthly Payment	100
Consulting Agreement, Performance Bonus, Target Value	$ 300
Accrued Bonuses, Current		$ 300		$ 300		$ 200
Consultation Agreement with Zachary Javitt [Member] \| Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	50,000
Consultation Agreement with Zachary Javitt [Member] \| Restricted Stock [Member] \| Unrestricted Upon New Drug Application Date [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	25,000
Consultation Agreement with Zachary Javitt [Member] \| Restricted Stock [Member] \| Unrestricted Upon New Drug Approval Date [member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	25,000

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - USD ($)					9 Months Ended
Note 14 - Subsequent Event (Details Textual) - USD ($)	Oct. 31, 2024	Oct. 31, 2024	Oct. 10, 2024	Aug. 15, 2024	Sep. 30, 2024	Sep. 30, 2023	Oct. 14, 2024
Debt Issuance Costs					$ 521,000	$ 0
Streetervile Complaint [Member]
Payments for Legal Settlements				$ 2,500,000
Subsequent Event [Member] \| Conversion of Anson Notes to Common Stock [Member]
Debt Conversion, Converted Instrument, Amount	$ 800,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)	754,152
Subsequent Event [Member] \| Streetervile Complaint [Member]
Payments for Legal Settlements		$ 3,050,000	$ 3,050,000
Subsequent Event [Member] \| Anson Warrants Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,846,128
Anson Second Tranche Notes [Member] \| Subsequent Event [Member]
Debt Instrument, Face Amount			$ 5,435,000				$ 5,435,000
Long-Term Debt, Gross			$ 5,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 1.7664
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			92%
Placement Agent Fee, Percent of Gross Proceeds			7%
Debt Issuance Costs			$ 400,000
Anson Second Tranche Notes [Member] \| Subsequent Event [Member] \| Maximum [Member]
Placement Agent, Expenses Reimbursed			$ 50,000